Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edurne Arriola

Showing results (21-30 of 90) with videos related to

Pageof 9
Sort By:
Journal of Clinical Medicine|April 20, 2019
EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with AdenocarcinomaRoberto Chalela, Beatriz Bellosillo, Víctor Curull, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 7, 2023
SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)Rosario García-Campelo, Ivana Sullivan, Edurne Arriola, et al.
Journal of Chemotherapy (Florence, Italy)|December 3, 2020
Prognostic factors and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer treated with immune checkpoint blockageDavid Conde-Estévez, Inés Monge-Escartín, Alejandro Ríos-Hoyo, et al.
Neuropathology and Applied Neurobiology|July 26, 2021
CD8 T-cell-mediated cerebellitis directed against Purkinje cell antigen after ipilimumab for small cell lung cancerMarc Hardwick, Luke Nolan, James A R Nicoll, et al.
Clinical Lung Cancer|May 28, 2017
Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC SamplesDavid Casadevall, Sergi Clavé, Álvaro Taus, et al.
The Journal of Dermatology|November 20, 2020
Diffuse dermal mucinosis secondary to colony-stimulating factor 1 receptor monoclonal antibody treatment: A novel and peculiar drug-induced diffuse cutaneous mucinosisFerran Olmos-Alpiste, Sonia Segura, Alejandra Tomás-Velázquez, et al.
Lung Cancer (Amsterdam, Netherlands)|October 3, 2015
Angiopoietin-2 is a negative prognostic marker in small cell lung cancerIsrael Cañadas, Álvaro Taus, Xavier Villanueva, et al.
Journal of Clinical Pathology|December 13, 2006
MYC amplification in breast cancer: a chromogenic in situ hybridisation studyS Maria Rodriguez-Pinilla, Robin L Jones, Maryou B K Lambros, et al.
The Oncologist|November 25, 2023
Feasibility and User Experience of Digital Patient Monitoring for Real-World Patients With Lung or Breast CancerEdurne Arriola, Jana Jaal, Anne Edvardsen, et al.
Future Oncology (London, England)|November 14, 2025
Osimertinib before and after chemoradiotherapy for unresectable stage III EGFR-mutated NSCLC: NEOLA Trial ProtocolJacqueline V Aredo, Nir Peled, Edurne Arriola, et al.
Pageof 9

Showing results (21-30 of 90) with videos related to

Sort By:
Pageof 9
Journal of Clinical Medicine|April 20, 2019
EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with AdenocarcinomaRoberto Chalela, Beatriz Bellosillo, Víctor Curull, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 7, 2023
SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)Rosario García-Campelo, Ivana Sullivan, Edurne Arriola, et al.
Journal of Chemotherapy (Florence, Italy)|December 3, 2020
Prognostic factors and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer treated with immune checkpoint blockageDavid Conde-Estévez, Inés Monge-Escartín, Alejandro Ríos-Hoyo, et al.
Neuropathology and Applied Neurobiology|July 26, 2021
CD8 T-cell-mediated cerebellitis directed against Purkinje cell antigen after ipilimumab for small cell lung cancerMarc Hardwick, Luke Nolan, James A R Nicoll, et al.
Clinical Lung Cancer|May 28, 2017
Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC SamplesDavid Casadevall, Sergi Clavé, Álvaro Taus, et al.
The Journal of Dermatology|November 20, 2020
Diffuse dermal mucinosis secondary to colony-stimulating factor 1 receptor monoclonal antibody treatment: A novel and peculiar drug-induced diffuse cutaneous mucinosisFerran Olmos-Alpiste, Sonia Segura, Alejandra Tomás-Velázquez, et al.
Lung Cancer (Amsterdam, Netherlands)|October 3, 2015
Angiopoietin-2 is a negative prognostic marker in small cell lung cancerIsrael Cañadas, Álvaro Taus, Xavier Villanueva, et al.
Journal of Clinical Pathology|December 13, 2006
MYC amplification in breast cancer: a chromogenic in situ hybridisation studyS Maria Rodriguez-Pinilla, Robin L Jones, Maryou B K Lambros, et al.
The Oncologist|November 25, 2023
Feasibility and User Experience of Digital Patient Monitoring for Real-World Patients With Lung or Breast CancerEdurne Arriola, Jana Jaal, Anne Edvardsen, et al.
Future Oncology (London, England)|November 14, 2025
Osimertinib before and after chemoradiotherapy for unresectable stage III EGFR-mutated NSCLC: NEOLA Trial ProtocolJacqueline V Aredo, Nir Peled, Edurne Arriola, et al.
Pageof 9